


RSC Advances



This article can be cited before page numbers have been issued, to do this please use: A. Saha, S. Payra, S. K. Verma, S. Thareja, S. Banerjee and M. Mandal, *RSC Adv.*, 2015, DOI: 10.1039/C5RA16643H.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



Journal Name

ARTICLE

In-silico binding affinity to cyclooxygenase-II and green synthesis of benzylpyrazolyl coumarin derivatives

Arijit Saha^a, Soumen Payra^a, Sant Kumar Verma^b, Mou Mandal^a, Suresh Thareja^b and Subhash Banerjee^{a,*}

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Here, we have reported for the first time, in-silico binding affinity prediction of benzylpyrazolyl coumarin scaffolds to cyclooxygenase-II (COX-II) enzyme and a green synthetic route to access these scaffolds using a neutral ionic liquid, [pmlm]Br as the reusable catalyst and reaction media under metal-free conditions. Integrated scaffolds, benzylpyrazolyl coumarins exhibited stronger binding affinity to COX-II inhibitor than its individual moieties, 3-benzyl coumarins and pyrazolones. Moreover, 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-nitrophenyl)methyl)-5-methyl-2-phenyl-1H-pyrazol-3(2H)-one (3c) has shown even better binding affinity than marketed anti-inflammatory drug, celecoxib.

Design and development of integrated molecular scaffolds for the biological applications has fascinated much attention as these moieties exhibit wide and improved bio-activities. In this connection, 3-benzyl substituted coumarins are of much interest as these moieties showed broad range of biological activities and consequently these moieties were found in many of the natural products namely as warfarin, phenprocumene and coumatetralyl which were reported to show antibacterial, anti-HIV,^{1a} antiviral,^{1b} anticoagulant,^{1c} antioxidant^{1d} and anticancer activities^{1e} (Fig. 1a). On the other hand, pyrazolones have also exhibit broad spectrum of biological activities and few of them for example, phenazone, propyphenazone, ampyrone and edarvone are well known as antipyretic and analgesic drugs (Fig. 1b).² In addition, pyrazolones are also recognized as antimicrobial, antifungal,^{3a} antimycobacterial,^{3b} antibacterial,^{3c} anti-inflammatory,^{3d,e} antitumor,^{3f} gastric secretion stimulatory,^{3g} antidepressant,^{3h} antifilarial activities³ⁱ and anti-tubercular activities.^{3j} It is anticipated that the integration of the 3-benzyl coumarin and pyrazolone moieties leading to benzylpyrazolyl coumarin scaffolds (Fig. 1c) could be fascinating and beneficial from the biological point of view. However, interestingly, binding affinity and selectivity of benzylpyrazolyl coumarin derivatives against any biological target has not been investigated.

Over past decades, nonsteroidal anti-inflammatory drugs (NSAIDs) are of enormous importance as therapeutics for the

treatment of pain and inflammation, predominantly arthritis.⁴ In this connection, design and development of NSAIDs are of much importance to overcome the general limitations of present drugs such as GI bleeding, ulceration, perforation, and obstruction etc.⁵




Fig. 1 Some bioactive individual (a) 3-benzyl substituted coumarins, (b) pyrazolones and (c) model integrated scaffold.

The major pharmacological mechanism of action of NSAIDs is the enzymatic inhibition of cyclooxygenase (COX) mediated production of pro-inflammatory prostaglandins and thromboxanes. COX and Lipoxygenase (LOX) are the key enzymes which catalyze the rate-limiting steps in the biosynthesis of prostaglandins and leukotrienes from arachidonic acid.⁶ The two different forms of the COX enzymes

^a Department of Chemistry, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur-495009, Chhattisgarh, India.

^b School of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur-495009, Chhattisgarh, India.

†Electronic Supplementary Information (ESI) available: Plausible mechanism for the synthesis of benzylpyrazolyl coumarins, Reusability of [pmlm]Br, Preparative method for the synthesis of benzylpyrazolyl coumarin derivatives, Methods for the Preparation of ionic liquids, Copies of ¹H NMR, ¹³C NMR spectra and HPLC data of benzylpyrazolyl coumarin derivatives. See DOI: 10.1039/x0xx00000x

are COX-I (constitutive) and COX-II (inducible), respectively. COX-I is expressed in many organs and is responsible for homeostatic processes such as platelet aggregation, gastric protection, and renal function while COX-II enzyme induced in response to the release of several pro-inflammatory mediators leading to the inflammatory response and pain.⁷ However, simultaneous inhibition of COX-I results the gastrointestinal toxicities and the mild bleeding diathesis.⁸ Whereas, COX-II enzyme was found to be anti-inflammatory, responsible for the selective inhibition but non-ulcerogenic in both the carrageenin-induced inflammation and the adjuvant arthritis.⁹ Therefore, the research in the field of inflammation around the world relies on the search of potent, selective and specific inhibitors of the COX-II.

Computer aided drug design tools have been widely used for the prediction of biological activity, toxicity, binding modes, selectivity and screening of a library of synthetic compounds against a particular biological target. It is evident from the literature that the pyrazolones widely exhibits COX-II inhibitory activity.^{3d,e} Here, we have evaluated their binding affinity against COX-II inhibitor enzyme of integrated benzylpyrazolyl coumarin scaffolds (3a-g, Fig. 2) and compared with those of individual moieties of pyrazolones (1a-b, Fig. 2) and 3-benzyl coumarins (2a-e, Fig. 2).




Fig. 2 Structure of individual pyrazolones (1a-b), 3-benzyl coumarins (2a-e) and their integrated scaffold, benzylpyrazolyl coumarins (3a-g).

Molecular docking technique is used in the present study for the comparison of binding affinity and selectivity of parent scaffolds and their integrated complex against COX-II. Molegro virtual docker (MVD 2013.6.0.0 evaluation version) was used for the flexible docking study of parent scaffolds and their union complexes with COX-II which is based on molecular docking simulations such as intramolecular interaction energy of the ligand (E_{intra}), ligand and macromolecular interaction energy *i.e.* intermolecular interaction energy (E_{inter}) and docking scoring function (E_{score}). Initially, for performing molecular docking, the 3D structures of COX-II, molecular mechanics (MM2) and Hamiltonian approximation (AM1) optimized (both the optimizers were run till the root-mean-square gradient value reaches a value smaller than 0.001 kcal/mol Å) parent scaffolds and their union complexes were

imported into the workspace. During import process, intense care should be taken that all the crystallographic water molecules were removed from COX-II. Further, COX-II and all the ligands were subjected to molecules preparation. The secondary structure of COX-II with co-factors is presented in Fig. 3. Five distinct cavities (See Fig.S1 in ESI-1) with different surface area and volume have been mapped within COX-II (PDB Id.:4COX) using detect cavity module in MVD software.¹⁰




Fig. 3 Secondary structure of COX-II enzyme showing its co-factors and cavity 1.

During this computational process, the maximum numbers of cavities were fixed to 5, grid resolution 0.80 Å and probe size 1.2 Å; while the other parameters were kept as default. The volume and surface area of these cavities are depicted in Table 1.

Table 1 Major cavities (1-5) detected in COX-II along with their volume and surface area

Cavity No.	Volume (Å ³)	Surface Area (Å ²)
1	1561.090	3776.000
2	1426.940	3566.080
3	1370.620	3257.600
4	698.880	1539.840
5	242.688	807.680

The Cavity 1 (Fig. 5) has highest volume (1561.090Å³) along with largest surface area (3776.000Å²). The key residues of cavity 1 included Ala 151, Arg 44, Arg 469, Asn 39, Asn 43, Asp 125, Cys 36, Cys 47, Gln 42, Gln 46, Glu 46, Glu 465, Gly 45, Leu 152, Lys 468, Lys 546, Pro 40, Pro 153, Ser 38, Ser 471, Tyr 130, Tyr 466 (Fig. 4). For performing docking the option docking wizard in docking window was selected and the docking algorithm was set to MolDock Simplex Evolution (MolDock SE) with population size 50. RMSD thresholds were set 1.00 Å for cluster similar poses as well as for ignore similar poses (for multiple runs only) both. Number of independent runs were selected ten and each of these runs was returning to a single final solution *i.e.* pose. Only negative lowest-energy representative cluster was returned from each of them after

completion of docking and the similar poses were removed keeping the best scoring one. The clusters were ranked through compare the conformation of the lowest binding energy in each cluster. The first minimum binding free energy pose was selected for the analysis of the docking results. Other parameters such as binding radius, grid resolution and maximum iterations parameters were set to 15 Å, 0.3 Å and 1,500 respectively.¹¹




Fig. 4 Showing cavity 1 (green colour) of COX-II with amino acid residues.

Further, MolDock score, Re-rank score and H-bond score, obtained after docking simulation are the markers of the affinity of the parent scaffolds and their integration complexes with COX-II (Table 2). These scores permit us to recognize the significant interactions take place between different conformations of each ligand and the amino acid residues present in active site of COX-II in order to get best minimum energy conformation of each ligand.¹²

Table 2 Moldock score, re-rank score and H-Bond score of parent ligands and their integration complexes

Ligand	MolDock Score	H-Bond Score	Re-rank Score
1a	-58.282	-3.182	-47.830
2a	-105.935	0.000	-92.001
3a	-134.877	-6.372	-104.615
1b	-92.549	-2.294	-80.324
2a	-105.935	0.000	-92.001
3b	-145.568	-4.964	-118.887
1b	-92.549	-2.294	-80.324
2b	-124.023	-5.744	-106.286
3c	-162.027	-3.399	-105.214
1b	-92.549	-2.294	-80.324
2c	-113.784	-2.076	-98.150
3d	-154.438	-1.524	-113.761
1b	-92.549	-2.294	-80.324
2d	-118.953	-1.560	-101.978

3e	-150.385	-6.167	-124.305
1b	-92.549	-2.294	-80.324
2e	-118.182	-3.627	-97.152
3f	-154.521	-0.238	-124.316
1a	-58.282	-3.182	-47.830
2e	-118.182	-3.627	-97.152
3g	-152.536	-5.173	-114.596
Celecoxib	-156.232	-2.680	-126.570

It is sighted from the Table 2 that the MolDock scores and re-rank scores of all the integration complexes (3a-g) were greater than that of their parent scaffolds. The compound, **3c** demonstrated highest MolDock score (**-162.027**) with comparable re-rank score (**-105.214**) which are even greater than celecoxib, a marketed selective COX-II inhibitor and signifies its better affinity and selectivity towards COX-II (Table 2). The hydrogen bond and steric interactions of **3c** with COX-II is depicted in Fig.5 and Fig.6 respectively.




Fig. 5 Hydrogen bonds labeled in dash bonds as 1 and 2 (A) and steric (B) interactions of **3c** with COX-II.





Fig. 6 H-bond interactions (dash bonds shown in yellow color, labeled with 1 and 2) of compound 3c with in cavity 1 (red colored amino acids: hydrophilic, blue colored amino acids: hydrophobic) of COX-II.

The integrated molecular scaffolds possess diverse range of functionalities (e.g. nitro, methoxy, keto, hydroxy, phenyl etc.) for the desired H-bonding and electrostatic interactions with the amino acid moieties of COX-II enzyme, which results significant enhancement of binding affinity and selectivity of integrated benzylpyrazolyl coumarin derivatives to COX-II inhibitor compared to individual moieties.

Thus, the computer aided modeling data successfully demonstrated that the integrated scaffolds (3a-g) selectively and specifically binds with the amino acid residues present in the cavity of COX-II inhibitor to a greater extent compared to the individual moieties (1a-b and 2a-e). Motivated by these results, we have tried to establish a green synthetic route to access these scaffolds (3a-g) under neutral and metal-free reaction conditions. The literature reports indicate that only three methods are available for the synthesis of benzyl pyrazolyl coumarin scaffolds^{12a-c} (Fig. 1c). These methods have utilized either glacial acetic acid,^{13a} or lanthanide^{13b}/alkaline earth^{13c} metal as catalyst. Thus, development of a metal-free green synthetic protocol for the synthesis of scaffold, 3 is highly desirable.

Over decades, ionic liquids (ILs) were reported to act as green alternative reaction media¹⁴ and efficient catalysts¹⁵ in organic synthesis. Here, we have observed remarkable catalytic activity of a neutral IL, pentyl methyl imidazolium bromide, [pmlm]Br for the one-pot four component synthesis of benzylpyrazolyl coumarin derivatives at room temperature (Scheme 1).



Scheme 1 Synthesis of benzylpyrazolyl coumarin derivatives using [pmlm]Br at room temperature.

Here, [pmlm]Br acts as both catalyst and reaction medium and no other metal catalysts or organic solvents were used for this synthesis.

Initially, we have chosen synthesis of 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(phenyl)methyl)-5-methyl-3H-pyrazol-3-one via a four component reaction of benzaldehyde, ethyl acetoacetate, hydrazine hydrate and 4-hydroxy coumarin as a model reaction. When a stoichiometric amount of four components mixed in [pmlm]Br (2 ml) at room temperature for 2 h good yield (85 %) of product was obtained (entry 1, Table 3). The same reaction was failed to produce desired product even at elevated temperature (80 °C) without ionic liquid under neat or in water (entry 2, Table 3).

Table 3 Optimization of reaction conditions

Entry	Ionic Liquid	Time (h)	Yield (%) ^a
1	[pmlm]Br	2	85
2	No ionic liquid or H ₂ O/80°C	4	-
3	[Acmlm]Cl	2	35
4	[Acmlm]Cl ^b	2	69
5	[pmlm]Br ^c	2	74

Reaction conditions: ethyl acetoacetate (1 mmol), phenyl hydrazine (1 mmol), benzaldehyde (1 mmol), 4-hydroxycoumarin (1 mmol), ionic liquid (2 ml), room temperature, continuous stirring. ^aIsolated yield. ^bHeating at 70 °C, ^c1 ml of [pmlm]Br was used.

Using acidic ionic liquid, [Acmlm]Cl only 35% product was isolated at room temperature (entry 3, Table3). However, the yield has increased to 69% at 70°C (entry 4, Table 3). Thus, the reaction using neutral ionic liquid, [pmlm]Br at room temperature was considered as optimized conditions for the synthesis of benzylpyrazolyl coumarin derivatives.

Next, we have explored the scope of this protocol for the generation of a library of benzylpyrazolyl coumarin derivatives. The results were listed in Table 4. A variety of aryl aldehydes containing different substituent (e.g. -NO₂, -Cl, -OMe, -Me etc.) participated in this multicomponent reaction to provide the excellent yields (85-90%) of products within practical time period (2 h) and electronic effect of the substituent present in aromatic aldehyde was not observed.

However, slight lower yields of the products were observed in reactions when phenyl hydrazine is used in place of hydrazine. This could be due to the delocalization of lone pair of one nitrogen atom to the phenyl ring. After the reactions the compounds were separated from ionic liquids and recrystallized from hot ethanol and characterized primarily by checking their melting points and compared these values with the reported values. Further, the structure and purity of

compounds were re-confirmed by ^1H NMR and ^{13}C NMR studies (ESI-6) as well as high performance liquid chromatography (HPLC) study (see ESI-7).

Table 4 Synthesis of benzylpyrazolyl coumarins using [pmlm]Br

Entry	(3a-g)	Time (h)	Yield (%) ^a	Melting Point (°C)	
				Observed	Reported ^{ref}
1		2.0	85	229-231	231-233 ^{13a}
2		2.5	85	232-234	232-234 ^{13a}
3		2.0	87	248-249	248-250 ^{13a}
4		2.0	88	228-230	227-229 ^{13a}
5		2.5	86	223-225	222-224 ^{13a}
6		2.5	85	204-206	205-207 ^{13a}
7		2.0	90	200-201	202-204 ^{13a}
Reaction condition: ethyl acetoacetate (1mmol), hydrazine hydrate/phenyl hydrazine (1mmol), 4-hydroxycoumarin (1mmol), aryl aldehyde (1 mmol), [pmlm]Br (2ml), room temperature with continuous stirring. ^a isolated yield.					

In order to compare the results of synthesis of benzylpyrazolyl coumarin using [pmlm]Br with those of reported protocols, a comparative study of catalytic performance is presented in Table 5. This study clearly indicates that the present protocol better alternative to those of existing as present protocol avoided metal catalysts.

The synthesis of benzylpyrazolyl coumarins proceeds through the catalytic cycle involving simultaneous synthesis of two intermediates, pyrazolone (I) and 3-arylidenechroman-2,4-dione (II) from general condensation and Knoevenagel

condensation reaction respectively. Subsequently, the two intermediates react to each other *via* Michael addition followed by cyclization and tautomerization to afford the benzylpyrazolyl coumarin derivatives. A plausible mechanistic pathway has been presented in ESI-4.

Table 5 Comparative results of catalysts for the synthesis of benzylpyrazolyl coumarin derivatives

Entry	Catalyst	Reaction condition	Time	Yield (%)	Ref.
1	[bmlm]Br	Neat/RT/ 25 °C	2-2.5 h	85-90	This work
2	Gl. AcOH	H ₂ O/ Reflux	30-55 min.	80-94	13a
3	ZrO ₂ NPs	EtOH- H ₂ O/RT/ 25 °C	2-7 min.	93-97	13b
4	Ca(OTf) ₂ / Bu ₄ NPF ₆	H ₂ O/ 100 °C	3-5 h	68-91	13c

Conclusions

In conclusion, we have demonstrated enhanced target specific molecular binding affinities of integrated molecular scaffolds, benzylpyrazolyl coumarins with COX-IIinhibitor. Moreover, It is noteworthy that the 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-nitrophenyl)methyl)-5-methyl-2-phenyl-1H-pyrazol-3(2H)-one (3c) moiety has exhibited even better affinity in terms of H-bonds score and re-rank score than marketed anti-inflammatory drug, celecoxib. Additionally, here we have developed a green and synthetic methodology to access benzylpyrazolyl coumarin moieties *via* a facile one-pot multicomponent reaction using a neutral ionic liquid at room temperature. Here, ionic liquids act as both catalyst and reaction medium and of course performed the reactions under neutral conditions. Finally, these scaffolds may further be used for the development of potential and COX-II specific anti-inflammatory agents.

Acknowledgment

We are pleased to acknowledge the funding agencies Department of Science and Technology, New Delhi, Govt. of India (NO.SB/FT/CS-023/2012). AS and SP thank to Guru Ghasidas Vishwavidyalaya and SKV thanks ICMR for their fellowship. We are also thankful to Dr. Rene Thomsen for providing permission to use MVD software, Prof. B. C. Ranu and Dr. K. V. S. Ranganath and their groups for helping in NMR and HPLC studied.

Notes and references

1. (a) S. Hesse and G. Kirsch, *Tetrahedron Lett.*, 2002, **43**, 1213; (b) B. H. Lee, M. F. Clothier, F. E. Dutton, G. A. Conder and S. S. Johnson, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 3317; (c) J. -C. Jung, Y. -J. Jung and O.-S. Park, *Synth. Commun.*, 2001, **31**, 1195; (d) G. Melagraki, A. Afantitis, O. Igglessi-Markopoulou, A. Detsi, M. Koufaki, C. Kontogiorgis and D. J. Hadjipavlou-Litina, *Eur. J. Med. Chem.*, 2009, **44**, 3020; (e) J.-C. Jung, J.-H. Lee, S. Oh, J.-G. Lee and O.-S. Park, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 5527.
2. T. W. Wu, L. H. Zeng, J. Wu and K. P. Fung, *Life Sci.*, 2002, **71**, 2249.
3. (a) M. A. Al-Haiza, S. A. El-Assiery and G. H. Sayed, *Acta Pharm. (Zagreb, Croatia)*, 2001, **51**, 251; (b) D. Castagnolo, F. Manetti, M. Radi, B. Bechi, M. Pagano, A. De Logu, R. Meleddu, M. Saddi and M. Botta, *Bioorg. Med. Chem.*, 2009, **17**, 5716; (c) F. Moreau, N. Desroy, J. M. Genevard, V. Vongsouthi, V. Gerusz, G. LemFralliec, C. Oliveira, S. Floquet, A. Denis, S. Escaich, K. Wolf, M. Busemann and A. Aschenbsenner, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 4022; (d) E. A. M. Badawey and I. M. El-Ashmawey, *Eur. J. Med. Chem.*, 1998, **33**, 349; (e) M. E. A. Zaki, H. A. Saliman, O. A. Hickal and A. E. Z. Rashad, *Naturforsch., C: Biosci.*, 2006, **61**, 1; (f) F. A. Pasha, M. Muddassar, M. M. Neaz and S. J. Cho, *J. Mol. Graphics Modell.*, 2009, **28**, 54; (g) C. E. Rosiere and M. I. Grossman, *Science*, 1951, **113**, 651; (h) D. M. Bailey, P. E. Hansen, A. G. Hlavac, E. R. Baizman, J. Pearl, A. F. Defelice and M. E. Feigenson, *J. Med. Chem.*, 1985, **28**, 256; (i) P. M. S. Chauhan, S. Singh and R. K. Chatterjee, *Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.*, 1993, **32**, 858; (j) P. Gunasekaran, S. Perumal, P. Yogeeswari and D. Sriram, *Eur. J. Med. Chem.*, 2011, **46**, 4530.
4. K. Rullah, M. F. M. Aluwi, B. M. Yamin, M. S. Baharuddin, N. H. Ismail, H. Y. Teruna, S. N. A. Bukhari, I. Jantan, J. Jalil, K. Husain, L. K. Wai, *J. Mol. Biol.*, 2015, **1081**, 51.
5. (a) G. Singh, D. Ramey, D. Morfeld, H. Shi, H. T. Hatoum, J.F. Fries, *Arch. Intern. Med.*, 1996, **156**, 1530; (b) F. K. L. Chan, *Nat. Clin. Pract. Gastroenterol. Hepatol.*, 2006, **3**, 563.
6. A. Kumar, B. Ahmed, B. Srivastawa, Vaishali, *Der Pharma. Chem.*, 2012, **4**, 383.
7. (a) M. Amir, H. Kumar, S. A. Javed, *Eur. J. Med. Chem.*, 2008, **43**, 2056; (b) M. F. E. Shehry, A. A. Abu-Hashem, E. M. E. Telbani, *Eur. J. Med. Chem.*, 2010, **45**, 1906.
8. G. A. FitzGerald, C. N. Patrono, *N. Engl. J. Med.*, 2001, **345**, 433.
9. (a) J. L. Masferrer, B. S. Zweifel, P. T. Manning, *Proc. Natl. Acad. Sci. USA.*, 1994, **91**, 3228; (b) G. D. Anderson, S. D. Hauser, K. L. McGarity, M. E. Bremer, P. C. Isakson, S. A. Gregory, *J. Clin. Invest.*, 1996, **97**, 2672.
10. Protein data bank. An information portal to biological macromolecular structures. <http://www.rcsb.org/pdb/explore/explore.do?structureId=4C OX> (Accessed on: July 27, 2015).
11. J. Sochacka, B. Pawelczak, *Acta Pol. Pharm. Drug Res.*, 2012, **69**, 161.
12. R. Thomsen, M. H. Christensen, *J. Med. Chem.*, 2006, **49**, 3315.
13. (a) P. P. Ghosh, G. Pal, S. Pal, A. R. Das, *Green Chem.*, 2012, **14**, 2691; (b) A. Saha, S. Payra, S. Banerjee, *Green Chem.*, 2015, **17**, 2859; (c) S. Yaragorla, A. Pareek, R. Dada, *Tetrahedron Lett.*, 2015, **56**, 4770.
14. (a) T. Welton, *Chem. Rev.*, 1999, **99**, 2071; (b) P. Wasserscheid, W. Keim, *Angew. Chem., Int. Ed.*, 2000, **39**, 3773; (c) R. Sheldon, *Chem. Commun.*, 2001, 2399. (d) J. S. Wilkes, *Green Chem.*, 2002, **4**, 73.
15. (a) B. C. Ranu, S. Banerjee, *Org. Lett.*, 2005, **7**, 3049; (b) B. C. Ranu, A. Saha, S. Banerjee, *Eur. J. Org. Chem.*, 2008, **3**, 519; (c) B. C. Ranu, L. Adak, S. Banerjee, *Tetrahedron Lett.*, 2008, **49**, 4613.

Graphical Abstract

In-silico binding affinity to cyclooxygenase-II and green synthesis of benzylpyrazolyl coumarin derivatives

Arijit Saha^a, Soumen Payra^a, Sant Kumar Verma^b, Mou Mandal, Suresh Thareja^b and Subhash Banerjee^{a,*}

Here, we have reported for the first time, in-silico binding affinity prediction of benzylpyrazolyl coumarin scaffolds to cyclooxygenase-II (COX-II) enzyme and a green synthetic route to access these scaffolds using a neutral ionic liquid, [pmIm]Br as the reusable catalyst and reaction media under metal-free conditions. Integrated scaffolds, benzylpyrazolyl coumarins exhibited stronger binding affinity to COX-II inhibitor than its individual moieties, 3-benzyl coumarins and pyrazolones. Moreover, 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-nitrophenyl)methyl)-5-methyl-2-phenyl-1H-pyrazol-3(2H)-one (3c) has shown even better binding affinity than marketed anti-inflammatory drug, celecoxib.

